Abstract
Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.
Keywords: Immunotherapy, immunotargets, metastatic renal cell carcinoma, kidney cancer.
Current Drug Targets
Title:Emerging Immunotargets in Metastatic Renal Cell Carcinoma
Volume: 17 Issue: 7
Author(s): John Kucharczyk, Marc R. Matrana, Matteo Santoni, Francesco Massari, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Stefano Cascinu, Rodolfo Montironi and Moch Holger
Affiliation:
Keywords: Immunotherapy, immunotargets, metastatic renal cell carcinoma, kidney cancer.
Abstract: Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.
Export Options
About this article
Cite this article as:
Kucharczyk John, R. Matrana Marc, Santoni Matteo, Massari Francesco, Scarpelli Marina, Cheng Liang, Lopez-Beltran Antonio, Cascinu Stefano, Montironi Rodolfo and Holger Moch, Emerging Immunotargets in Metastatic Renal Cell Carcinoma, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450117666151209115753
DOI https://dx.doi.org/10.2174/1389450117666151209115753 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Requirements and Perspectives for Integrating Metabolomics with other Omics Data
Current Metabolomics Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Estrogens and Progression of Diabetic Kidney Damage
Current Diabetes Reviews The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design Developments in Synthesis of the Anti-inflammatory Drug, Celecoxib: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Mechanisms of HIV Neuropathogenesis: Role of Cellular Communication Systems
Current HIV Research The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action
Current Drug Targets Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry From TGF-β to Cancer Therapy
Current Drug Targets Insight View on Synthetic Strategies and Biological Applications of Pyrimidobenzothiazoles
Mini-Reviews in Organic Chemistry OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry CD4 Down-Modulating Compounds with Potent Anti-HIV Activity
Current Pharmaceutical Design Gallium-68: A New Trend in PET Radiopharmacy
Current Radiopharmaceuticals Wnt Signaling in Renal Cancer
Current Drug Targets